SCHEDULE 13G/A: Soleus Capital Group Amends Axogen, Inc. Stake, Maintains 3.7% Passive Ownership

Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have filed an Amendment No. 3 to their Schedule 13G, disclosing a continued beneficial ownership of 3.7% in Axogen, Inc. common stock as of March 31, 2025.

Summary

• Soleus Capital Master Fund, L.P., along with its related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 1,446,117 shares of Axogen, Inc. common stock.
• This ownership represents 3.7% of Axogen, Inc.'s outstanding common stock.
• The percentage is calculated based on 44,343,785 shares of Axogen, Inc. common stock outstanding as of February 19, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on February 26, 2025.
• The shares are held directly by Soleus Capital Master Fund, L.P., with the other reporting persons having shared voting and dispositive power.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Axogen, Inc., indicating a passive investment strategy.

Sentiment

Score: 5

Explanation: The document is neutral as it is a routine regulatory filing (Schedule 13G Amendment) disclosing a passive ownership stake, with no inherent positive or negative implications for the company's operations or financial performance.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Axogen, Inc.'s future performance or the reporting persons' future investment intentions beyond their passive stance.

Industry Context

This Schedule 13G filing is a routine disclosure by an institutional investor group, Soleus Capital, regarding its passive stake in Axogen, Inc., a company in the medical technology or biotechnology sector. Such filings are standard regulatory requirements for investors holding significant, but non-controlling, positions in publicly traded companies. It does not provide specific insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, but passive, institutional ownership stake in Axogen, Inc.

Key Dates

Keywords

Axogen Inc., Soleus Capital, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Investment Management, AXGN